aTyr Pharma (LIFE)
(Delayed Data from NSDQ)
$1.73 USD
-0.03 (-1.70%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.74 +0.01 (0.58%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
aTyr Pharma, Inc. [LIFE]
Reports for Purchase
Showing records 81 - 100 ( 174 total )
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
''1923''s Efficacy Signal in COVID-19 Supports Its Anti-Inflammatory MOA
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Pulmonary Sarcoidosis Study is Fully Enrolled, Data Expected in 3Q2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Randomized Data Right Around the Corner; 3Q20 Results
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Update - Multiple Updates With Catalysts Starting by YE2020/2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
ATYR-1923 COVID-19 Study - NRP-2 Antibody Plans Progress. Reiterate Buy.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Here''s Why aTyr''s COVID-19 Study Enrollment Completion Is Material
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Key Takeaways From Our Mgmt Talk Series
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
We See a Positive Shift in aTyr Tide; Upgrade to Buy and $13 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Earnings-Don''t Lose Sight of aTyr as It Approaches YE2020 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
ATyr''s Partner Kyorin Initiated Phase 1 Study of ATYR1923 in Japan
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z